Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase [clinicaltrials:NCT00905593]
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase [clinicaltrials:NCT00905593]
Bio2RDF identifier
NCT00905593
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00905593
identifiers.org URI
acronym [clinicaltrials_vocabulary:acronym]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
Multi-center, open-labe ...... 24 months of follow-up time.
brief title [clinicaltrials_vocabulary:brief-title]
Nilotinib in Adult Patients Wi ...... lerated Phase or Chronic Phase
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2009-05-18T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
accelerated phase,
blast crisis,
chronic myeloid leukemia,
chronic phase
intolerant,
nilotinib,
resistant,
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-07-17T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00905593
official title [clinicaltrials_vocabulary:official-title]
An Open-label, Multicenter Stu ...... lerated Phase or Chronic Phase
org study id [clinicaltrials_vocabulary:org-study-id]
CAMN107AMX01
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2011-04-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2008-09-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-07-01T00:00:00Z
identifier
clinicaltrials:NCT00905593
title
Nilotinib in Adult Patients Wi ...... lerated Phase or Chronic Phase
@en
type
label
Nilotinib in Adult Patients Wi ...... e [clinicaltrials:NCT00905593]
@en